Crossmark

Response to PD1 inhibition in conventional chondrosarcoma

Crossref DOI link: https://doi.org/10.1186/s40425-018-0413-z

Published Online: 2018-09-25

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wagner, Michael J. https://orcid.org/0000-0002-0753-9282
Ricciotti, Robert W.

Mantilla, Jose

Loggers, Elizabeth T.

Pollack, Seth M.

Cranmer, Lee D.
Funding

Funding for this research was provided by:

ASCO-Conquer Cancer Foundation (11305)

QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research (17-4-37-WAGN)
License Information

Text and Data Mining valid from 2018-09-25
More Information

Article History

Received: 25 July 2018

Accepted: 18 September 2018

First Online: 25 September 2018

Consent for publication

: Informed consent was obtained from the patient prior to preparation of this case report.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.